Abdullah Mahmood, MD
Interventional Cardiology · Birmingham, ALNPI 1922521012
Payments from drug & device makers
What this record shows
This record is dominated by grants: $53,490 of the $61,373 with a category attached, or 87.2%. 19 manufacturers reported payments, led by Abbott at 38.8% of the total. Reporting peaked in 2024 at $51,578 and has fallen 98.1% since, to $967 in 2025. Among interventional cardiology clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 229 payments — averaging $268.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$24K
- Boston Scientific$20K
- Medtronic$15K
- Cvrx, Inc.$651
- Edwards Lifesciences$597
- Abiomed$445
- plus $1K from 13 others
Across 1 payment — averaging $49.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abiomed$50
What the payments were for
- Grants$53,49087%
- Travel & lodging$2,5824%
- Food & beverage$5,2028%
- Education$990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 29 | $23,792 |
| Boston Scientific | 13 | $19,684 |
| Medtronic | 85 | $15,005 |
| Cvrx, Inc. | 4 | $651 |
| Edwards Lifesciences | 36 | $597 |
| Abiomed | 7 | $445 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 27 | $257 |
| Chiesi USA, Inc. | 3 | $157 |
| ZOLL Circulation Inc | 1 | $144 |
| Astellas Pharma US Inc | 6 | $134 |
| Merck | 6 | $130 |
| Inari Medical, Inc. | 1 | $113 |
| E.r. Squibb & Sons, L.L.C. | 4 | $71 |
| Johnson & Johnson | 2 | $49 |
| Janssen Scientific Affairs, LLC | 1 | $42 |
| Sanofi-aventis U.S. LLC | 1 | $32 |
| Amgen | 1 | $31 |
| Kestra Medical Technology Services, Inc. | 1 | $24 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$10,731
- VersaCross Access Solution$1,399
- Barostim Neo System$651
- Impella$300
- CARDIOMEMS$163
- TherOx DS2 Console$144
- Catheter$144
- Downstream Cartridge$144
- WOLVERINE CORONARY CUTTING BALLOON$140
- WATCHMAN Access System$138
- WATCHMAN FLX$137
- SAPIEN 3 Ultra RESILIA$117
- FLOWTRIEVER CATHETER, S$113
- CT THROMBECTOMY SYSTEM KIT$113
How this compares
$61,373 in reported general payments places this provider in the 90th percentile of 109 interventional cardiology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other interventional cardiology in Birmingham
- Gary RoubinBirmingham$157K
- Robert FosterBirmingham$90K
- Hasan GuvenBirmingham$86K
- Ali EbrahimiBirmingham$55K
- Jacob TownsendBirmingham$52K
- Kamran AliBirmingham$47K
- Mouhamed SabouniBirmingham$44K
- David SchultzBirmingham$19K
- Tushar MishraBirmingham$17K
- Arka ChatterjeeBirmingham$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.